Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Clinical trial NCT05501561 · COMPLETED

Trial details

NCT number: NCT05501561
Sponsor: Seqirus
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Influenza, Human

Start date: 2022-08-25
Primary completion: 2023-03-31
Enrollment: 1056

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.